In the program, Mr. Perrin discussed InVivo’s spinal cord injury treatment and how the patients are progressing. The information includes:
1. Treatment options for spinal cord injury patients — InVivo’s Neuro-Spinal Scaffold.
2. Two of the three patients in the company’s trial reported regaining either motor recovery, sensory recovery or bladder control.
3. The company plans to enroll a probable benefit trial after working with the FDA.
4. The company is designated as a humanitarian device exemption to get through the FDA process and hopes to have the scaffold on the market in the next few years.
5. The healthcare system spends well over a million dollars in the first year and high costs after that to care for these patients, so helping patients recover could have an impact on lowering future costs.
More articles on orthopedic devices:
Global orthopedic products market forecast to 2020: 5 points
Medtronic short interest drops 1.1%: 5 key notes
LDR launches 30-day public offering: 5 key notes
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
